Estudo da toxicidade e atividade antitumoral do derivado acridínico n’-(2-cloro-6-metoxi-acridin-9-yl)-2-ciano-3-(4-dimetilaminofenil)-acrilohidrazida em modelo experimental de tumor ascítico de ehrlich

• Autor(a) principal: Mangueira , Vivianne Mendes
• Data de Publicação: 2015
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UFPB
• Texto Completo: https://repositorio.ufpb.br/jspui/handle/tede/8821
• topic: Derivado Acridínico; Atividade Antitumoral; Tumor de Ehrlich; Toxicidade; Acridine- Derived; Antitumor Activity; Ehrlich Ascites Tumor; Toxicity; CIENCIAS BIOLOGICAS::FARMACOLOGIA

Cancer is a major public health problem worldwide and is considered a group of diseases characterized by uncontrolled growth and multiplication of abnormal cells that can invade various tissues. Treatment has been benefited from research that seek to reduce toxicity and increase the effectiveness of different anticancer drugs. Acridine derivatives have a number of proven biological activities, and amsacrine, an antineoplastic used for the treatment of leukemias and lymphomas, is the main representative of the group. This study aimed to evaluate the toxicity and antitumor activity of acridine- derived N’-(2-chloro-6-methoxy-acridin-9-yl)-2-cyano-3-(4-dimethylaminophenyl)-acrilohydrazide (ACS-AZ10). In the assessment of cytotoxicity in mouse erythrocytes it was observed that ACS-AZ10 did not cause hemolysis at the concentrations tested (up to 1250 μg / ml), suggesting low toxicity in erythrocytes. After acute administration of ACS-AZ10 (2000 mg / kg) in mice intraperitoneally (ip), characteristic effects of changes in the central nervous system among them, writhing and abduction of the legs of the rear train, were observed. The estimated LD50 (dose that produces death in 50% of experimental animals) was around 2500 mg / kg. The ACS-AZ10 (15 or 30 mg / kg), after a nine days treatment (ip) showed significant antitumor activity in vivo in Ehrlich ascites carcinoma model (EAC), considering the volume parameters, mass, viability and total cell count. Treatment at the dose 7.5 mg/kg induced an increase in sub-G1 peak, with a consequent reduction in the percentage of cells in G0/G1 and S phases of cell cycle, suggesting death by apoptosis. However, treatment with 15 mg/kg induced cell cycle arrest in G2/M phase and a reduction of the fraction G0/G1 and S, suggesting a pre-mitotic blockade. The treatment with different doses of ACS-AZ10 significantly reduced the angiogenic capacity of the EAC, thus it can be inferred that the ACS-AZ10´s antitumor mechanism of action involves, at least in part, an anti-angiogenic effect. The toxicological analysis indicated that after nine days of treatment with ACS-AZ10, low haematological and biochemical toxicity were observed. Histopathological analysis indicated liver damage following treatment with ACS-AZ10, however, the damage was considered mild and reversible. ACS-AZ10 induced no increase in the quantity of micronucleated erythrocyte in micronucleus test, indicating the absence of genotoxic under the conditions evaluated. Therefore, it is possible to infer that the ACS-AZ10 has potent antitumor activity in vivo with low toxicity.